Physical and functional interactions between Daxx and STAT3

Oncogene

Volumn 25, Issue 14, 2006, Pages 2131-2136

  Muromoto, R ^a   Nakao, K ^a   Watanabe, T ^a   Sato, N ^a   Sekine, Y ^a   Sugiyama, K ^b   Oritani, K ^c   Shimoda, K ^d   Matsuda, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Daxx; IL 6; LIF; STAT3; Transcriptional regulation

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; DAXX PROTEIN; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

ARTICLE; AUTOIMMUNE DISEASE; CANCER CELL CULTURE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HELA CELL; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSCRIPTION REGULATION; UTERINE CERVIX CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE; CELL NUCLEUS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPRECIPITATION; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 33645530423     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209235     Document Type: Article

References (23)

1. Brender C, Nielsen M, Ropke C, Nissen MH, Svejgaard A, Billestrup N et al. (2001). Exp Clin Immunogenet 18: 80-85.
2. Bromberg J. (2000). Breast Cancer Res 2: 86-90.
3. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. (1999). Cell 98: 295-303.
4. Darnell Jr JE, Kerr IM, Stark GR. (1994). Science 264: 1415-1421.
5. Hirano T, Nakajima K, Hibi M. (1997). Cytokine Growth Factor Rev 8: 241-252.
6. Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R, Grosveld G. (2002). J Cell Sci 115: 3319-3330.
7. Hollenbach AD, Sublett JE, McPherson CJ, Grosveld G. (1999). EMBO J 18: 3702-3711.
8. Ihle JN. (1995). Nature 377: 591-594.
9. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). J Cell Biol 147: 221-234.
10. Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. (1997). J Clin Invest 99: 447-456.
11. Kim EJ, Park JS, Um SJ. (2003). Nucleic Acids Res 31: 5356-5367.
12. Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL et al. (1999). Mol Med 5: 11-20.
13. Levy DE, Lee CK. (2002). J Clin Invest 109: 1143-1148.
14. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ et al. (2000a). Mol Cell Biol 20: 1784-1796.
15. Li R, Pei H, Watson DK, Papas TS. (2000b). Oncogene 19: 745-753.
16. Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C et al. (2004). J Invest Dermatol 123: 737-745.
17. Muromoto R, Sugiyama K, Takachi A, Imoto S, Sato N, Yamamoto T et al. (2004a). J Immunol 172: 2985-2993.
18. Muromoto R, Sugiyama K, Yamamoto T, Oritani K, Shimoda K, Matsuda T. (2004b). Biochem Biophys Res Commun 316: 827-833.
19. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N et al. (1996). EMBO J 15: 3651-3658.
20. Platanias LC. (2005). Nat Rev Immunol 5: 375-386.
21. Shimoda K, Kamesaki K, Numata A, Aoki K, Matsuda T, Oritani K et al. (2002). J Immunol 169: 4707-4711.
22. Torii S, Egan DA, Evans RA, Reed JC. (1999). EMBO J 18: 6037-6049.
23. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP. (2000). J Exp Med 191: 631-640.